BidaskClub upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a strong sell rating to a sell rating in a research note published on Saturday, January 6th.
Other research analysts have also recently issued reports about the company. Piper Jaffray Companies reaffirmed a buy rating and set a $42.00 price objective on shares of Phibro Animal Health in a research report on Friday, November 10th. Zacks Investment Research raised Phibro Animal Health from a hold rating to a buy rating and set a $41.00 price objective for the company in a research report on Tuesday, October 31st. Finally, ValuEngine cut Phibro Animal Health from a buy rating to a hold rating in a research report on Thursday, November 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $38.25.
Phibro Animal Health (NASDAQ:PAHC) opened at $35.70 on Friday. The company has a current ratio of 3.26, a quick ratio of 1.85 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $1,434.53, a PE ratio of 21.00, a PEG ratio of 4.17 and a beta of 1.27. Phibro Animal Health has a 52-week low of $26.10 and a 52-week high of $40.25.
Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.01. The company had revenue of $193.40 million during the quarter, compared to analysts’ expectations of $189.89 million. Phibro Animal Health had a return on equity of 42.75% and a net margin of 8.87%. Phibro Animal Health’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.36 earnings per share. research analysts anticipate that Phibro Animal Health will post 1.57 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, December 27th. Investors of record on Wednesday, December 6th were given a dividend of $0.10 per share. The ex-dividend date was Tuesday, December 5th. This represents a $0.40 annualized dividend and a yield of 1.12%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 23.53%.
Hedge funds and other institutional investors have recently modified their holdings of the stock. KBC Group NV acquired a new position in Phibro Animal Health during the second quarter valued at approximately $166,000. Victory Capital Management Inc. boosted its position in Phibro Animal Health by 17.6% during the second quarter. Victory Capital Management Inc. now owns 5,380 shares of the company’s stock valued at $199,000 after purchasing an additional 807 shares during the last quarter. Capital Fund Management S.A. acquired a new position in Phibro Animal Health during the second quarter valued at approximately $210,000. Susquehanna International Group LLP acquired a new position in Phibro Animal Health during the second quarter valued at approximately $219,000. Finally, BNP Paribas Arbitrage SA boosted its position in Phibro Animal Health by 55.7% during the second quarter. BNP Paribas Arbitrage SA now owns 5,933 shares of the company’s stock valued at $220,000 after purchasing an additional 2,123 shares during the last quarter. 48.56% of the stock is owned by hedge funds and other institutional investors.
About Phibro Animal Health
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.